报价延迟最少15分钟:2026/04/18 07:14 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.72 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.16/3.50
|
|
企业价值
1.37B
|
| 资产负债 |
|
每股账面净值
17.12
|
| 现金流量 |
|
现金流量率
0.14
|
| 损益表 |
|
收益
726.41M
|
|
每股收益
16.44
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee. |
